NGNE Neurogene Inc

Price (delayed)

$27.68

Market cap

$437.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.56

Enterprise value

$322.03M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 6

neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed ...

Highlights
NGNE's debt is down by 22% year-on-year and by 8% since the previous quarter
NGNE's quick ratio is down by 38% YoY and by 21% from the previous quarter
Neurogene's net income has decreased by 22% YoY and by 9% QoQ

Key stats

What are the main financial stats of NGNE

NGNE stock price

How has the Neurogene stock price performed over time
Intraday
5.57%
1 week
0.65%
1 month
-1.91%
1 year
27.73%
YTD
34.37%
QTD
37.3%

Financial performance

How have Neurogene's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$110.76M
Net income
-$98.64M
Gross margin
N/A
Net margin
N/A
NGNE's operating income is down by 22% year-on-year and by 7% since the previous quarter
Neurogene's net income has decreased by 22% YoY and by 9% QoQ

Price vs fundamentals

How does NGNE's price correlate with its fundamentals

Growth

What is Neurogene's growth rate over time

Valuation

What is Neurogene stock price valuation
P/E
N/A
P/B
1.81
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NGNE's EPS is down by 8% QoQ and by 4.8% YoY
The stock's price to book (P/B) is 56% more than its last 4 quarters average of 1.1 and 32% more than its 5-year quarterly average of 1.3
NGNE's equity is down by 19% YoY and by 10% QoQ

Efficiency

How efficient is Neurogene business performance
The company's return on invested capital fell by 25% QoQ but it rose by 2.6% YoY
The ROE has contracted by 15% from the previous quarter and by 4.7% YoY
NGNE's return on assets is down by 14% since the previous quarter and by 7% year-on-year

Dividends

What is NGNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NGNE.

Financial health

How did Neurogene financials performed over time
NGNE's quick ratio is down by 38% YoY and by 21% from the previous quarter
Neurogene's current ratio has decreased by 38% YoY and by 21% QoQ
NGNE's debt is 96% smaller than its equity
NGNE's debt is down by 22% year-on-year and by 8% since the previous quarter
NGNE's equity is down by 19% YoY and by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.